Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04858256 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Site contacts updated at 1 of 6 sitesv15
  2. Eligibility criteria expanded, about 98 words
    • Study description expanded, about 21 words
    • Collaborators: 2 to 4
    v14
  3. Site details revised at 1 of 6 sitesv13
  4. Eligibility criteria expanded, about 288 wordsv12
  5. Site details revised at 2 of 6 sitesv11
Show 9 earlier versionsHide 9 earlier versions
  1. Study sites: 1 to 6v10
  2. Primary completion date: Mar 1, 2025 to Nov 2027
    • Study completion date: Mar 1, 2028 to Nov 2028
    v9
  3. Trial status: Not Yet Recruiting to Recruitingv8 Show 4 more changesShow less
    • Primary completion date: Apr 1, 2025 to Mar 1, 2025
    • Study completion date: Apr 1, 2028 to Mar 1, 2028
    • Start date changed from estimate of Apr 2023 to Mar 29, 2023
    • Site details revised
  4. Start date: Feb 2023 to Apr 2023
    • Primary completion date: Feb 1, 2025 to Apr 1, 2025
    • Study completion date: Feb 1, 2028 to Apr 1, 2028
    • Site contact updated
    v7
  5. Start date: Dec 2022 to Feb 2023
    • Primary completion date: Dec 1, 2024 to Feb 1, 2025
    • Study completion date: Dec 1, 2027 to Feb 1, 2028
    v6
  6. Primary completion date: Mar 1, 2024 to Dec 1, 2024
    • Start date: Aug 31, 2022 to Dec 2022
    • Study completion date: Mar 1, 2027 to Dec 1, 2027
    v5
  7. Start date: Jul 1, 2022 to Aug 31, 2022v4
  8. Start date: Mar 1, 2022 to Jul 1, 2022
    • Collaborators: 1 to 2
    v3
  9. Primary completion date: Jun 2023 to Mar 1, 2024
    • Start date: Jun 2021 to Mar 1, 2022
    • Study completion date: Jun 2026 to Mar 1, 2027
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The main purpose of this study is to determine the effectiveness of the study drug pacritinib in people with relapsed or refractory lymphoproliferative disorders.
Trial Details
NCT Number NCT04858256
Lead Sponsor University of Michigan Rogel Cancer Center
Collaborators: National Institutes of Health (NIH), National Cancer Institute (NCI), Hoosier Cancer Research Network, CTI BioPharma
Conditions
(from sponsor)		 T-Cell Neoplasm, Lymphoproliferative Disorders
Related terms Lymphoproliferative Disorders
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov